-
1
-
-
0038318967
-
Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases
-
Kovarik JM, Burtin P. Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin. Emerg. Drugs 8, 47-62 (2003).
-
(2003)
Expert Opin. Emerg. Drugs
, vol.8
, pp. 47-62
-
-
Kovarik, J.M.1
Burtin, P.2
-
2
-
-
0042971650
-
Molecular interactions mediating T-cell antigen recognition
-
van der Merwe PA, Davis SJ. Molecular interactions mediating T-cell antigen recognition. Annu. Rev. Immunol. 21, 659-684 (2003).
-
(2003)
Annu. Rev. Immunol.
, vol.21
, pp. 659-684
-
-
van der Merwe, P.A.1
Davis, S.J.2
-
5
-
-
0036072614
-
Targeting T-cell costimulation in autoimmune disease
-
Racke MK, Stuart RW. Targeting T-cell costimulation in autoimmune disease. Expert. Opin. Ther. Targets 6, 275-289 (2002).
-
(2002)
Expert. Opin. Ther. Targets
, vol.6
, pp. 275-289
-
-
Racke, M.K.1
Stuart, R.W.2
-
6
-
-
0036773925
-
Mechanisms of transplant tolerance induction using costimulatory blockade
-
Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr. Opin. Immunol. 14, 592-600 (2002).
-
(2002)
Curr. Opin. Immunol.
, vol.14
, pp. 592-600
-
-
Wekerle, T.1
Kurtz, J.2
Bigenzahn, S.3
Takeuchi, Y.4
Sykes, M.5
-
8
-
-
0027403299
-
The role of the CD28 receptor during T-cell responses to antigen
-
Linsley PS, Ledbetter JA. The role of the CD28 receptor during T-cell responses to antigen. Ann. Rev. Immunol. 11, 191-212 (1993).
-
(1993)
Ann. Rev. Immunol.
, vol.11
, pp. 191-212
-
-
Linsley, P.S.1
Ledbetter, J.A.2
-
10
-
-
0035059417
-
Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation
-
Salomon B, Bluestone JA. Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Ann. Rev. Immunol. 19, 225-252 (2001).
-
(2001)
Ann. Rev. Immunol.
, vol.19
, pp. 225-252
-
-
Salomon, B.1
Bluestone, J.A.2
-
11
-
-
0347505003
-
CD28-mediated co-stimulation: A quantitative support for TCR signalling
-
Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nature Rev. Immunol. 3, 939-951 (2003).
-
(2003)
Nature Rev. Immunol.
, vol.3
, pp. 939-951
-
-
Acuto, O.1
Michel, F.2
-
12
-
-
0026778697
-
Immunosuppression in vivo by a soluble form of the CTLA-4 T-cell activation molecule
-
Linsley PS, Wallace PM, Johnson J. et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T-cell activation molecule. Science 257, 792-795 (1992).
-
(1992)
Science
, vol.257
, pp. 792-795
-
-
Linsley, P.S.1
Wallace, P.M.2
Johnson, J.3
-
13
-
-
0028675006
-
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
-
Linsley PS, Greene JL, Brady W et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793-801 (1994).
-
(1994)
Immunity
, vol.1
, pp. 793-801
-
-
Linsley, P.S.1
Greene, J.L.2
Brady, W.3
-
14
-
-
0027937702
-
Complementary determining region 1 (CDR1) - CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1
-
Peach RJ, Bajorath J, Brady W et al. Complementary determining region 1 (CDR1) - CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 180, 2049-2058 (1994).
-
(1994)
J. Exp. Med.
, vol.180
, pp. 2049-2058
-
-
Peach, R.J.1
Bajorath, J.2
Brady, W.3
-
15
-
-
0031180381
-
Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28
-
Metzler WJ, Bajorath J, Fenderson W et al. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nature Struct. Biol. 4, 527-531 (1997).
-
(1997)
Nature Struct. Biol.
, vol.4
, pp. 527-531
-
-
Metzler, W.J.1
Bajorath, J.2
Fenderson, W.3
-
16
-
-
0035967146
-
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
-
Stamper CC, Zhang Y, Tobin JF et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410, 608-611 (2001).
-
(2001)
Nature
, vol.410
, pp. 608-611
-
-
Stamper, C.C.1
Zhang, Y.2
Tobin, J.F.3
-
17
-
-
0035967157
-
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
-
Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 410, 604-608 (2001).
-
(2001)
Nature
, vol.410
, pp. 604-608
-
-
Schwartz, J.C.1
Zhang, X.2
Fedorov, A.A.3
Nathenson, S.G.4
Almo, S.C.5
-
18
-
-
0031036085
-
CD80 costimulation is essential for the induction of airway eosinophilia
-
Harris N, Peach R, Naemura J. et al. CD80 costimulation is essential for the induction of airway eosinophilia. J. Exp. Med. 185, 177-182 (1997).
-
(1997)
J. Exp. Med.
, vol.185
, pp. 177-182
-
-
Harris, N.1
Peach, R.2
Naemura, J.3
-
19
-
-
0035871614
-
CD80 costimulation is required for Th2 cell cytokine production but not for antigen-specific accumulation and migration into the lung
-
Harris NL, Prout M, Peach RJ, Fazekas De St Groth B, Ronchese F. CD80 costimulation is required for Th2 cell cytokine production but not for antigen-specific accumulation and migration into the lung. J. Immunol. 166, 4908-4914 (2001).
-
(2001)
J. Immunol.
, vol.166
, pp. 4908-4914
-
-
Harris, N.L.1
Prout, M.2
Peach, R.J.3
Fazekas De St Groth, B.4
Ronchese, F.5
-
20
-
-
0036499924
-
Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: Suppression of helper t-cell type 1-dominated immune response
-
Tikkanen JM, Lemstrom KB, Koskinen PK. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper t-cell type 1-dominated immune response. Am. J. Respir. Crit. Care Med. 165, 724-729 (2002).
-
(2002)
Am. J. Respir. Crit. Care Med.
, vol.165
, pp. 724-729
-
-
Tikkanen, J.M.1
Lemstrom, K.B.2
Koskinen, P.K.3
-
21
-
-
33645444469
-
Soluble CTLA4 mutant molecules and uses thereof
-
Patent. WO0192337, (2001-12-06)
-
Bajorath J, Linsley PS, Peach RJ, Naemura JR. Soluble CTLA4 mutant molecules and uses thereof. Patent. WO0192337, (2001-12-06) (2001).
-
(2001)
-
-
Bajorath, J.1
Linsley, P.S.2
Peach, R.J.3
Naemura, J.R.4
-
22
-
-
33645429990
-
Antibodies and immunoglobulin fusion proteins having modified effector fanctions and uses therefor
-
Patent. WO9728267, 1997-08-07
-
Gray GS, Siver S, Carson J. et al. Antibodies and immunoglobulin fusion proteins having modified effector fanctions and uses therefor. Patent. WO9728267, 1997-08-07 (1997).
-
(1997)
-
-
Gray, G.S.1
Siver, S.2
Carson, J.3
-
23
-
-
0038546813
-
Mammary gland-specific secretion of biologically active immunosuppressive agent cytotoxic-T-lymphocyte antigen 4 human immunoglobulin fusion protein (CTLA4Ig) in milk by transgenesis
-
Lui VC, Tam PK, Leung MY et al. Mammary gland-specific secretion of biologically active immunosuppressive agent cytotoxic-T-lymphocyte antigen 4 human immunoglobulin fusion protein (CTLA4Ig) in milk by transgenesis. J. Immunol. Methods 277, 171-183 (2003).
-
(2003)
J. Immunol. Methods
, vol.277
, pp. 171-183
-
-
Lui, V.C.1
Tam, P.K.2
Leung, M.Y.3
-
24
-
-
0029916381
-
A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice
-
Srinivas NR, Weiner RS, Shyu WC et al. A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice. J. Pharm. Sci. 85, 296-298 (1996).
-
(1996)
J. Pharm. Sci.
, vol.85
, pp. 296-298
-
-
Srinivas, N.R.1
Weiner, R.S.2
Shyu, W.C.3
-
25
-
-
0030805029
-
Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats
-
Srinivas NR, Shyu WC, Weiner RS et al. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. Pharm. Res. 14, 911-916 (1997).
-
(1997)
Pharm. Res.
, vol.14
, pp. 911-916
-
-
Srinivas, N.R.1
Shyu, W.C.2
Weiner, R.S.3
-
26
-
-
0029661755
-
Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses
-
Srinivas NR, Weiner RS, Warner G et al. Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J. Pharm. Sci. 85, 1-4 (1996).
-
(1996)
J. Pharm. Sci.
, vol.85
, pp. 1-4
-
-
Srinivas, N.R.1
Weiner, R.S.2
Warner, G.3
-
27
-
-
0033135564
-
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
-
Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103, 1243-1252 (1999).
-
(1999)
J. Clin. Invest.
, vol.103
, pp. 1243-1252
-
-
Abrams, J.R.1
Lebwohl, M.G.2
Guzzo, C.A.3
-
28
-
-
0036852242
-
When ligand becomes receptor-tolerance via B7 signaling on DCs
-
Finger EB, Bluestone JA. When ligand becomes receptor-tolerance via B7 signaling on DCs. Nature Immunol. 3, 1056-1057 (2002).
-
(2002)
Nature Immunol.
, vol.3
, pp. 1056-1057
-
-
Finger, E.B.1
Bluestone, J.A.2
-
29
-
-
0027397169
-
Induction of alloantigen-specific hyporesponsiveness in human T-lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
-
Tan P, Anasetti C, Hansen JA et al. Induction of alloantigen-specific hyporesponsiveness in human T-lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177, 165-173 (1993).
-
(1993)
J. Exp. Med.
, vol.177
, pp. 165-173
-
-
Tan, P.1
Anasetti, C.2
Hansen, J.A.3
-
30
-
-
0041474771
-
The effects of B7-dependent costimulation on T-cell division and survival in vivo and in vitro are dependent on antigen concentration
-
Lumsden JM, Prasad SJ, Peach RJ, Ronchese F. The effects of B7-dependent costimulation on T-cell division and survival in vivo and in vitro are dependent on antigen concentration. Eur. J. Immunol. 33, 2074-2082 (2003).
-
(2003)
Eur. J. Immunol.
, vol.33
, pp. 2074-2082
-
-
Lumsden, J.M.1
Prasad, S.J.2
Peach, R.J.3
Ronchese, F.4
-
31
-
-
33645430129
-
Abatacept (CTLA4Ig; BMS-188667) significantly inhibits the proliferation of human T-cells in vitro at clinically relevant concentrations
-
Federation of Clinical Immunology Societies Meeting, Montreal Canada. Abs. 3514
-
Nadler S, Townsend R, Mikesell G et al. Abatacept (CTLA4Ig; BMS-188667) significantly inhibits the proliferation of human T-cells in vitro at clinically relevant concentrations. Federation of Clinical Immunology Societies Meeting, Montreal Canada. Abs. 3514 (2004).
-
(2004)
-
-
Nadler, S.1
Townsend, R.2
Mikesell, G.3
-
32
-
-
0029871741
-
The in vivo mechanism of action of CTLA4Ig
-
Judge TA, Tang A, Spain LM et al. The in vivo mechanism of action of CTLA4Ig. J. Immunol. 156, 2294-2299 (1996).
-
(1996)
J. Immunol.
, vol.156
, pp. 2294-2299
-
-
Judge, T.A.1
Tang, A.2
Spain, L.M.3
-
33
-
-
0029665801
-
The time course of CTLA4Ig effect on cardiac allograft rejection
-
Bolling SF, Lin H, Turka LA. The time course of CTLA4Ig effect on cardiac allograft rejection. J. Surg. Res. 63, 320-323 (1996).
-
(1996)
J. Surg. Res.
, vol.63
, pp. 320-323
-
-
Bolling, S.F.1
Lin, H.2
Turka, L.A.3
-
34
-
-
0012465040
-
Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice
-
Szot GL, Zhou P, Rulifson I et al. Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice. Am. J. Transplant. 1, 38-46 (2001).
-
(2001)
Am. J. Transplant.
, vol.1
, pp. 38-46
-
-
Szot, G.L.1
Zhou, P.2
Rulifson, I.3
-
36
-
-
0036664289
-
Inability to induce tolerance through direct antigen presentation
-
Rulifson IC, Szot GL, Palmer E, Bluestone JA. Inability to induce tolerance through direct antigen presentation. Am. J. Transplant. 2, 510-519 (2002).
-
(2002)
Am. J. Transplant.
, vol.2
, pp. 510-519
-
-
Rulifson, I.C.1
Szot, G.L.2
Palmer, E.3
Bluestone, J.A.4
-
38
-
-
0030461047
-
CD28-B7 T-cell co-stimulatory blockade by CTLA4Ig in the rat renal allograft model. inhibition of cell mediated and humoral immune responses in vivo
-
Akalin E, Chandraker A, Russell ME et al. CD28-B7 T-cell co-stimulatory blockade by CTLA4Ig in the rat renal allograft model. inhibition of cell mediated and humoral immune responses in vivo. Transplantation 62, 1942-1945 (1996).
-
(1996)
Transplantation
, vol.62
, pp. 1942-1945
-
-
Akalin, E.1
Chandraker, A.2
Russell, M.E.3
-
39
-
-
0029834883
-
Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig
-
Cabrian KM, Berry KK, Shuford WW et al. Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig. Transplant. Proc. 28, 3261-3262 (1996).
-
(1996)
Transplant. Proc.
, vol.28
, pp. 3261-3262
-
-
Cabrian, K.M.1
Berry, K.K.2
Shuford, W.W.3
-
40
-
-
0029856233
-
CTLA4Ig inhibits alloantibody responses to repeated blood transfusions
-
Ibrahim S, Jakobs F, Kittur D et al. CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. Blood 88, 4594-4600 (1996).
-
(1996)
Blood
, vol.88
, pp. 4594-4600
-
-
Ibrahim, S.1
Jakobs, F.2
Kittur, D.3
-
41
-
-
0142213315
-
CTLA4-Ig abrogates die anti-globulin response and prolongs cardiac allograft survival after anti-CD2 treatment
-
Stell D, Marshall H, Bradley JA, Bolton EM. CTLA4-Ig abrogates die anti-globulin response and prolongs cardiac allograft survival after anti-CD2 treatment. Transpl. Immunol. 12, 1-7 (2003).
-
(2003)
Transpl. Immunol.
, vol.12
, pp. 1-7
-
-
Stell, D.1
Marshall, H.2
Bradley, J.A.3
Bolton, E.M.4
-
43
-
-
0033932756
-
CTLA4Ig inhibits T-cell-dependent B-cell maturation in murine systemic lupus erythematosus
-
Mihara M, Tan I, Chuzhin Y et al. CTLA4Ig inhibits T-cell-dependent B-cell maturation in murine systemic lupus erythematosus. J. Clin. Invest. 106, 91-101 (2000).
-
(2000)
J. Clin. Invest.
, vol.106
, pp. 91-101
-
-
Mihara, M.1
Tan, I.2
Chuzhin, Y.3
-
44
-
-
0026738641
-
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig
-
Lenschow DJ, Zeng Y, Thistlewaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257, 789-792 (1992).
-
(1992)
Science
, vol.257
, pp. 789-792
-
-
Lenschow, D.J.1
Zeng, Y.2
Thistlewaite, J.R.3
-
46
-
-
0028903939
-
CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
-
Sayegh MH, Akalin E, Hancock WW et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181, 1869-1874 (1995).
-
(1995)
J. Exp. Med.
, vol.181
, pp. 1869-1874
-
-
Sayegh, M.H.1
Akalin, E.2
Hancock, W.W.3
-
47
-
-
0030293507
-
Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig
-
Saha B, Jaklic B, Harlan DM et al. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J. Immunol. 157, 3869-3875 (1996).
-
(1996)
J. Immunol.
, vol.157
, pp. 3869-3875
-
-
Saha, B.1
Jaklic, B.2
Harlan, D.M.3
-
48
-
-
0038784372
-
Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura
-
Peng J, Liu C, Liu D et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood 101, 2721-2726 (2003).
-
(2003)
Blood
, vol.101
, pp. 2721-2726
-
-
Peng, J.1
Liu, C.2
Liu, D.3
-
49
-
-
0026459468
-
T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo
-
Turka LA, Linsley PS, Bradt W et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89, 11102-11105 (1992).
-
(1992)
Proc. Natl. Acad. Sci. USA
, vol.89
, pp. 11102-11105
-
-
Turka, L.A.1
Linsley, P.S.2
Bradt, W.3
-
50
-
-
0029060729
-
Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment
-
Wallace PM, Rodgers JN, Leytze GM, Johnson JS, Linsley PS. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J. Immunol. 11, 5885-5895 (1995).
-
(1995)
J. Immunol.
, vol.11
, pp. 5885-5895
-
-
Wallace, P.M.1
Rodgers, J.N.2
Leytze, G.M.3
Johnson, J.S.4
Linsley, P.S.5
-
51
-
-
0027451441
-
Long term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
-
Lin H, Boiling SF, Linsley PS et al. Long term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178, 1801-1806 (1993).
-
(1993)
J. Exp. Med.
, vol.178
, pp. 1801-1806
-
-
Lin, H.1
Boiling, S.F.2
Linsley, P.S.3
-
52
-
-
0035746174
-
Tolerance through bone marrow transplantation with costimulation blockade
-
Wakerle T, Blaha P, Langer F, Schmid M, Muehlbacher F. Tolerance through bone marrow transplantation with costimulation blockade. Transpl. Immunol. 9, 125-133 (2002).
-
(2002)
Transpl. Immunol.
, vol.9
, pp. 125-133
-
-
Wakerle, T.1
Blaha, P.2
Langer, F.3
Schmid, M.4
Muehlbacher, F.5
-
53
-
-
0029851220
-
Blockade of multiple co-stimulatory receptors induces hyporesponsiveness. Inhibition of CD2 plus CD28 pathways
-
Woodward JE, Qin L, Chavin KD et al. Blockade of multiple co-stimulatory receptors induces hyporesponsiveness. Inhibition of CD2 plus CD28 pathways. Transplantation 62, 1011-1018 (1996).
-
(1996)
Transplantation
, vol.62
, pp. 1011-1018
-
-
Woodward, J.E.1
Qin, L.2
Chavin, K.D.3
-
54
-
-
15844404353
-
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
-
Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434-438 (1996).
-
(1996)
Nature
, vol.381
, pp. 434-438
-
-
Larsen, C.P.1
Elwood, E.T.2
Alexander, D.Z.3
-
55
-
-
0029898878
-
Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand
-
Tang A, Judge TA, Nickoloff BJ, Turka LA. Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand. J. Immunol. 157, 117-125 (1996).
-
(1996)
J. Immunol.
, vol.157
, pp. 117-125
-
-
Tang, A.1
Judge, T.A.2
Nickoloff, B.J.3
Turka, L.A.4
-
56
-
-
0037469060
-
Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway
-
Kosuge H, Suzuki J, Gotoh R et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 75, 1374-1379 (2003).
-
(2003)
Transplantation
, vol.75
, pp. 1374-1379
-
-
Kosuge, H.1
Suzuki, J.2
Gotoh, R.3
-
57
-
-
10744223143
-
Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation
-
Guo L, Fujino M, Kimura H et al. Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation. Tanspl. Immunol. 12, 41-48 (2003).
-
(2003)
Tanspl. Immunol.
, vol.12
, pp. 41-48
-
-
Guo, L.1
Fujino, M.2
Kimura, H.3
-
59
-
-
0030966217
-
Induction of peripheral T-cell tolerance in vivo requires CTLA-4 engagement
-
Perez VL, Parijs LV, Biuckians A et al. Induction of peripheral T-cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411-417 (1997).
-
(1997)
Immunity
, vol.6
, pp. 411-417
-
-
Perez, V.L.1
Parijs, L.V.2
Biuckians, A.3
-
60
-
-
10744226680
-
Transplantation tolerance through enhanced CTLA-4 expression
-
Ariyan C, Salvalaggio P, Fecteau S et al. Transplantation tolerance through enhanced CTLA-4 expression. J. Immunol. 171, 5673-5677 (2003).
-
(2003)
J. Immunol.
, vol.171
, pp. 5673-5677
-
-
Ariyan, C.1
Salvalaggio, P.2
Fecteau, S.3
-
61
-
-
0035102196
-
CTLA-4 regulates induction of anergy in vivo
-
Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity 14, 145-155 (2001).
-
(2001)
Immunity
, vol.14
, pp. 145-155
-
-
Greenwald, R.J.1
Boussiotis, V.A.2
Lorsbach, R.B.3
Abbas, A.K.4
Sharpe, A.H.5
-
62
-
-
2942586924
-
CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T-cell tolerance
-
Eagar TN, Turley DM, Padilla J et al. CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T-cell tolerance. J. Immunol. 172, 7442-7450 (2004).
-
(2004)
J. Immunol.
, vol.172
, pp. 7442-7450
-
-
Eagar, T.N.1
Turley, D.M.2
Padilla, J.3
-
63
-
-
0033557716
-
The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival
-
Judge TA, Wu Z, Zheng XG et al. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162, 1947-1951 (1999).
-
(1999)
J. Immunol.
, vol.162
, pp. 1947-1951
-
-
Judge, T.A.1
Wu, Z.2
Zheng, X.G.3
-
64
-
-
0036852170
-
CTLA-4-Ig regulates tryptophan catabolism in vivo
-
Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nature Immunol. 3, 1097-1101 (2002).
-
(2002)
Nature Immunol.
, vol.3
, pp. 1097-1101
-
-
Grohmann, U.1
Orabona, C.2
Fallarino, F.3
-
65
-
-
0038215374
-
Tolerance, DCs and tryptophan: Much ado about IDO
-
Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24, 242-248 (2003).
-
(2003)
Trends Immunol.
, vol.24
, pp. 242-248
-
-
Grohmann, U.1
Fallarino, F.2
Puccetti, P.3
-
66
-
-
0042591467
-
Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T-cell clonal expansion
-
Mellor AL, Baban B, Chandler P et al. Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T-cell clonal expansion. J. Immunol. 171, 1652-1655 (2003).
-
(2003)
J. Immunol.
, vol.171
, pp. 1652-1655
-
-
Mellor, A.L.1
Baban, B.2
Chandler, P.3
-
67
-
-
1642396607
-
+) T-cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells
-
+) T-cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172, 4100-4110 (2004).
-
(2004)
J. Immunol.
, vol.172
, pp. 4100-4110
-
-
Munn, D.H.1
Sharma, M.D.2
Mellor, A.L.3
-
69
-
-
3242875233
-
Technology evaluation: Abatacept, Bristol-Myers Squibb
-
Dumont FJ. Technology evaluation: abatacept, Bristol-Myers Squibb. Curr. Opin. Mol. Ther. 6, 318-330 (2004).
-
(2004)
Curr. Opin. Mol. Ther.
, vol.6
, pp. 318-330
-
-
Dumont, F.J.1
-
70
-
-
0035884819
-
An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection
-
Ferrari-Lacraz S, Zheng XX, Kim YS et al. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J. Immunol. 167, 3478-3485 (2001).
-
(2001)
J. Immunol.
, vol.167
, pp. 3478-3485
-
-
Ferrari-Lacraz, S.1
Zheng, X.X.2
Kim, Y.S.3
-
71
-
-
0036467337
-
The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts
-
Jones TR, Ha J, Williams MA et al. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts. J. Immunol. 168, 1123-1130 (2002).
-
(2002)
J. Immunol.
, vol.168
, pp. 1123-1130
-
-
Jones, T.R.1
Ha, J.2
Williams, M.A.3
-
72
-
-
0036023131
-
CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely
-
Corbascio M, Ekstrand H, Osterholm C et al. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transpl. Immunol. 10, 55-61 (2002).
-
(2002)
Transpl. Immunol.
, vol.10
, pp. 55-61
-
-
Corbascio, M.1
Ekstrand, H.2
Osterholm, C.3
-
73
-
-
0345164351
-
Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment
-
Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 66, 1387-1388 (1998).
-
(1998)
Transplantation
, vol.66
, pp. 1387-1388
-
-
Li, Y.1
Zheng, X.X.2
Li, X.C.3
Zand, M.S.4
Strom, T.B.5
-
74
-
-
1642412617
-
The antagonism of calcineurin inhibitors and costimulatory blockers: Fact or fiction?
-
Izawa A, Sayegh MH, Chandraker A. The antagonism of calcineurin inhibitors and costimulatory blockers: fact or fiction? Tansplant. Proc. 36, S570-S573 (2004).
-
(2004)
Tansplant. Proc.
, vol.36
-
-
Izawa, A.1
Sayegh, M.H.2
Chandraker, A.3
-
75
-
-
0030051268
-
Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T-cell and macrophage activation and attenuates arteriosclerosis
-
Russell ME, Hancock WW, Akalin E et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T-cell and macrophage activation and attenuates arteriosclerosis. J. Clin. Invest. 97, 833-838 (1996).
-
(1996)
J. Clin. Invest.
, vol.97
, pp. 833-838
-
-
Russell, M.E.1
Hancock, W.W.2
Akalin, E.3
-
76
-
-
0032103321
-
Late blockade of T-cell costimulation interrupts progression of experimental chronic allograft rejection
-
Chandraker A, Azuma H, Nadeau K et al. late blockade of T-cell costimulation interrupts progression of experimental chronic allograft rejection. J. Clin. Invest. 101, 2309-2318 (1998).
-
(1998)
J. Clin. Invest.
, vol.101
, pp. 2309-2318
-
-
Chandraker, A.1
Azuma, H.2
Nadeau, K.3
-
77
-
-
0035101515
-
CD28-B7-mediated T-cell costimulation in chronic cardiac allograft rejection: Differential role of B7-1 in initiation versus progression of graft arteriosclerosis
-
Kim KS, Denton MD, Chandraker A et al. CD28-B7-mediated T-cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 158, 977-986 (2001).
-
(2001)
Am. J. Pathol.
, vol.158
, pp. 977-986
-
-
Kim, K.S.1
Denton, M.D.2
Chandraker, A.3
-
78
-
-
0030944223
-
Importance of the CD28/B7 co-stimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation
-
Mark W, Hechenleitner P, Sayegh MH, Hancock WW, Candinas D. Importance of the CD28/B7 co-stimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation. Transplant. Proc. 29, 1029 (1997).
-
(1997)
Transplant. Proc.
, vol.29
, pp. 1029
-
-
Mark, W.1
Hechenleitner, P.2
Sayegh, M.H.3
Hancock, W.W.4
Candinas, D.5
-
79
-
-
3342878380
-
New strategies for the treatment of chronic rejection
-
Hoerbelt R, Muniappan A, Madsen JC, Allan JS. New strategies for the treatment of chronic rejection. Curr. Opin. Invest. Drugs. 5, 489-498 (2004).
-
(2004)
Curr. Opin. Invest. Drugs.
, vol.5
, pp. 489-498
-
-
Hoerbelt, R.1
Muniappan, A.2
Madsen, J.C.3
Allan, J.S.4
-
80
-
-
0029125813
-
Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules
-
Hakim FT, Cepeda R, Gray GS, June CH, Abe R. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. J. Immunol. 155, 1757-1766 (1995).
-
(1995)
J. Immunol.
, vol.155
, pp. 1757-1766
-
-
Hakim, F.T.1
Cepeda, R.2
Gray, G.S.3
June, C.H.4
Abe, R.5
-
81
-
-
2442689006
-
Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation
-
Anasetti C. Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation. Transplantation 77, S79-SS83 (2004).
-
(2004)
Transplantation
, vol.77
-
-
Anasetti, C.1
-
82
-
-
0033214355
-
Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant
-
Storb R, Yu C, Zaucha JM et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood. 94, 2523-2529 (1999).
-
(1999)
Blood
, vol.94
, pp. 2523-2529
-
-
Storb, R.1
Yu, C.2
Zaucha, J.M.3
-
83
-
-
0031307384
-
Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation
-
Levisetti MG, Padrid PA, Szot GL et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J. Immunol. 159, 5187-5191 (1997).
-
(1997)
J. Immunol.
, vol.159
, pp. 5187-5191
-
-
Levisetti, M.G.1
Padrid, P.A.2
Szot, G.L.3
-
84
-
-
12644262358
-
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
-
Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci USA. 94, 8789-8794 (1997).
-
(1997)
Proc. Natl. Acad. Sci. USA
, vol.94
, pp. 8789-8794
-
-
Kirk, A.D.1
Harlan, D.M.2
Armstrong, N.N.3
-
85
-
-
0037108717
-
Anti-CD40 therapy extends renal allograft survival in rhesus macaques
-
Pearson TC, Trambley J, Odom K et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 74, 933-940 (2002).
-
(2002)
Transplantation
, vol.74
, pp. 933-940
-
-
Pearson, T.C.1
Trambley, J.2
Odom, K.3
-
86
-
-
0032077806
-
Prolongation of cardiac graft survival with anti-CD4Ig plus hCTLA4Ig in primates
-
Krieger NR, Yuh D, Mcintyre WB et al. Prolongation of cardiac graft survival with anti-CD4Ig plus hCTLA4Ig in primates. J. Surg. Res. 76, 174-178 (1998).
-
(1998)
J. Surg. Res.
, vol.76
, pp. 174-178
-
-
Krieger, N.R.1
Yuh, D.2
Mcintyre, W.B.3
-
87
-
-
0036061575
-
Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates
-
Adams AB, Shirasugi N, Durham MM et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 51, 265-270 (2002).
-
(2002)
Diabetes
, vol.51
, pp. 265-270
-
-
Adams, A.B.1
Shirasugi, N.2
Durham, M.M.3
-
88
-
-
0033519661
-
Transplantation of anergic histoincompatible bone marrow allografts
-
Guinan EC, Boussiotis VA, Neubertg D et al. Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340, 1704-1714 (1999).
-
(1999)
N. Engl. J. Med.
, vol.340
, pp. 1704-1714
-
-
Guinan, E.C.1
Boussiotis, V.A.2
Neubertg, D.3
-
89
-
-
9744286455
-
Co-stimulation blockade with LEA29Y in renal transplant: Improved renal function and CV/metabolic profile at 6 months compared with cyclosporine
-
American Transplant Congress, Boston, USA. Abs. 1035
-
Nashan B, Grinyo J, Vincenti F et al. Co-stimulation blockade with LEA29Y in renal transplant: improved renal function and CV/metabolic profile at 6 months compared with cyclosporine. American Transplant Congress, Boston, USA. Abs. 1035, (2004).
-
(2004)
-
-
Nashan, B.1
Grinyo, J.2
Vincenti, F.3
-
90
-
-
9744264217
-
Co-stimulation blockade with LEA29Y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-month efficacy and safety
-
American Transplant Congress, Boston, USA Abs. 1037
-
Vincenti F, Muehlbacher F, Nashan B et al. Co-stimulation blockade with LEA29Y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-month efficacy and safety. American Transplant Congress, Boston, USA Abs. 1037, (2004).
-
(2004)
-
-
Vincenti, F.1
Muehlbacher, F.2
Nashan, B.3
-
91
-
-
0031253956
-
Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways
-
Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. 159, 3104-3108 (1997).
-
(1997)
J. Immunol.
, vol.159
, pp. 3104-3108
-
-
Daikh, D.I.1
Finck, B.K.2
Linsley, P.S.3
Hollenbaugh, D.4
Wofsy, D.5
-
92
-
-
0037083423
-
Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus
-
Wang X, Huang W, Mihara M, Sinha J, Davidson A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J. Immunol. 168, 2046-2053 (2002).
-
(2002)
J. Immunol.
, vol.168
, pp. 2046-2053
-
-
Wang, X.1
Huang, W.2
Mihara, M.3
Sinha, J.4
Davidson, A.5
-
93
-
-
0035284737
-
Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide
-
Daikh DI, Wofsy D. Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166, 2913-1916 (2001).
-
(2001)
J. Immunol.
, vol.166
, pp. 1916-2913
-
-
Daikh, D.I.1
Wofsy, D.2
-
94
-
-
0037868032
-
Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition
-
Schiffer L, Sinha J, Wang X et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J. Immunol. 171, 489-497 (2003).
-
(2003)
J. Immunol.
, vol.171
, pp. 489-497
-
-
Schiffer, L.1
Sinha, J.2
Wang, X.3
-
95
-
-
2342495275
-
Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide
-
Cunnane G, Chan OT, Cassafer G et al. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum 50, 1539-1548 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, pp. 1539-1548
-
-
Cunnane, G.1
Chan, O.T.2
Cassafer, G.3
-
96
-
-
0029849012
-
Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-I and B7-2
-
Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-I and B7-2. Eur. J. Immunol. 26, 2320-2328 (1996).
-
(1996)
Eur. J. Immunol.
, vol.26
, pp. 2320-2328
-
-
Webb, L.M.1
Walmsley, M.J.2
Feldmann, M.3
-
97
-
-
0037420518
-
Psoriasis
-
Lebwohl M. Psoriasis. Lancet 361, 1197-1204 (2003).
-
(2003)
Lancet
, vol.361
, pp. 1197-1204
-
-
Lebwohl, M.1
-
98
-
-
0034605033
-
Blockade of T-lymphocyte costimulation with cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
-
Abrams JR, Kelley SL, Hayes E et al. Blockade of T-lymphocyte costimulation with cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192, 681-693 (2000).
-
(2000)
J. Exp. Med.
, vol.192
, pp. 681-693
-
-
Abrams, J.R.1
Kelley, S.L.2
Hayes, E.3
-
99
-
-
0000415293
-
New concepts in the treatment of rheumatoid arthritis
-
Goldbach-Mansky R. Lipsky PE. New concepts in the treatment of rheumatoid arthritis. Ann. Rev. Med. 54, 197-216 (2003).
-
(2003)
Ann. Rev. Med.
, vol.54
, pp. 197-216
-
-
Goldbach-Mansky, R.1
Lipsky, P.E.2
-
100
-
-
0036275436
-
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
-
Moreland LW, Alten R, Van Den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46, 1470-1479 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 1470-1479
-
-
Moreland, L.W.1
Alten, R.2
Van Den Bosch, F.3
-
101
-
-
0242574700
-
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
-
Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003).
-
(2003)
N. Engl. J. Med.
, vol.349
, pp. 1907-1915
-
-
Kremer, J.M.1
Westhovens, R.2
Leon, M.3
-
102
-
-
33645430269
-
CTLA4Ig (BMS-188667) in a phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving methrotexate showed correlation between the clinical response and key biomarkers
-
Abs. 0157
-
Emery P, Westhovens R, Moreland L et al. CTLA4Ig (BMS-188667) in a phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving methrotexate showed correlation between the clinical response and key biomarkers. Ann. Rheum. Dis. 62, Abs. 0157 (2003).
-
(2003)
Ann. Rheum. Dis.
, pp. 62
-
-
Emery, P.1
Westhovens, R.2
Moreland, L.3
-
103
-
-
33645441119
-
Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
-
Westhovens R, Van Riel P, Sibilia J. et al. Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment. Arthritis Res. Ther. 6, 86 (2004).
-
(2004)
Arthritis Res. Ther.
, vol.6
, pp. 86
-
-
Westhovens, R.1
Van Riel, P.2
Sibilia, J.3
-
104
-
-
33645440397
-
CTLA4Ig (BMS-188667), a co-stimulation blocker, improved physical function in patients with active rheumatoid arthritis using methotrexate
-
Abs. 0227
-
Tugwell P, Emery P, Li T et al. CTLA4Ig (BMS-188667), a co-stimulation blocker, improved physical function in patients with active rheumatoid arthritis using methotrexate. Ann. Rheum. Dis. 62, Abs. 0227 (2003).
-
(2003)
Ann. Rheum. Dis.
, pp. 62
-
-
Tugwell, P.1
Emery, P.2
Li, T.3
-
105
-
-
4244023444
-
Impact on health-related quality of life following treatment with CTLA4Ig in patients with active rheumatoid arthritis using methotrexate
-
(Abs. 1377)
-
Emery P, Williams GR, Li T, Nuamah I, Becker JC. Impact on health-related quality of life following treatment with CTLA4Ig in patients with active rheumatoid arthritis using methotrexate. Arthritis Rheum. 46, S515 (Abs. 1377) (2002).
-
(2002)
Arthritis Rheum.
, vol.46
-
-
Emery, P.1
Williams, G.R.2
Li, T.3
Nuamah, I.4
Becker, J.C.5
-
106
-
-
33645426541
-
Improvement in health-related quality of life with treatment of CTLA4Ig (BMS-188667), a co-stimulation blocker, over one year in patients with active rheumatoid arthritis using methotrexate
-
American College of Rheumatology Meeting, Orlando, Florida, USA. Abs. 998
-
Emery P, Russell A, Kremer J. et al. Improvement in health-related quality of life with treatment of CTLA4Ig (BMS-188667), a co-stimulation blocker, over one year in patients with active rheumatoid arthritis using methotrexate. American College of Rheumatology Meeting, Orlando, Florida, USA. Abs. 998 (2003).
-
(2003)
-
-
Emery, P.1
Russell, A.2
Kremer, J.3
-
107
-
-
0013218378
-
A pilot, multicenter, randomized, double-blind, placebo-controlled (study) of a costimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis
-
(Abs. 464)
-
Weinblatt M, Schiff M, Goldmann M et al. A pilot, multicenter, randomized, double-blind, placebo-controlled (study) of a costimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis. Arthritis Rheum. 46, S204 (Abs. 464) (2002).
-
(2002)
Arthritis Rheum.
, vol.46
-
-
Weinblatt, M.1
Schiff, M.2
Goldmann, M.3
-
108
-
-
33645430269
-
CTLA4-Ig (BMS-188667) in a Phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: Association between clinical response and key biomarkers
-
Abs. 0225
-
Schiff M, Genoves M, Nuamah I, Becker J, Weinblatt M. CTLA4-Ig (BMS-188667) in a Phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: association between clinical response and key biomarkers. Ann. Rheum. Dis. 62, Abs. 0225 (2003).
-
(2003)
Ann. Rheum. Dis.
, pp. 62
-
-
Schiff, M.1
Genoves, M.2
Nuamah, I.3
Becker, J.4
Weinblatt, M.5
-
109
-
-
4244023469
-
Improvement in health-related quality of life in patients with active rheumatoid arthritis: CTLA4Ig combined with etanercept compared with etanercept plus placebo
-
Abs. 1376
-
Emery P, Williams GR, Li T, Breazna A, Becker JC. Improvement in health-related quality of life in patients with active rheumatoid arthritis: CTLA4Ig combined with etanercept compared with etanercept plus placebo. Arthritis Rheumat. 46, S514, Abs. 1376 (2002).
-
(2002)
Arthritis Rheumat.
, vol.46
-
-
Emery, P.1
Williams, G.R.2
Li, T.3
Breazna, A.4
Becker, J.C.5
-
110
-
-
12144290293
-
Calcineurin imposes T-cell unresponsiveness through targeted protelysis of signaling proteins
-
Heissmeyer V, Macian F, Im SH et al. Calcineurin imposes T-cell unresponsiveness through targeted protelysis of signaling proteins. Nature Immunol. 5, 255-265 (2004).
-
(2004)
Nature Immunol.
, vol.5
, pp. 255-265
-
-
Heissmeyer, V.1
Macian, F.2
Im, S.H.3
-
111
-
-
0030912016
-
CTLA4-Ig treatment prolongs rat orthotopic liver graft survival
-
Tu Y, Rehman A, Flye MW. CTLA4-Ig treatment prolongs rat orthotopic liver graft survival. Transpl. Proc. 29, 1036-1037 (1997).
-
(1997)
Transpl. Proc.
, vol.29
, pp. 1036-1037
-
-
Tu, Y.1
Rehman, A.2
Flye, M.W.3
-
112
-
-
0030447936
-
Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig
-
Yin D, Sankary HN, Williams J, Kreiger N, Fathman Cg. Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig. Transplantation 62, 1537-1539 (1996).
-
(1996)
Transplantation
, vol.62
, pp. 1537-1539
-
-
Yin, D.1
Sankary, H.N.2
Williams, J.3
Kreiger, N.4
Fathman, Cg.5
-
113
-
-
0028952480
-
Soluble CTLA4Ig modifies parameters of acute inflammation in rat lung allograft rejection without altering lymphocytic infiltration or transcription of key cytokines
-
Matsumura Y, Zuo XJ, Prehn J et al. Soluble CTLA4Ig modifies parameters of acute inflammation in rat lung allograft rejection without altering lymphocytic infiltration or transcription of key cytokines. Transplantation 59, 551-558 (1995).
-
(1995)
Transplantation
, vol.59
, pp. 551-558
-
-
Matsumura, Y.1
Zuo, X.J.2
Prehn, J.3
-
114
-
-
0037084322
-
Feasibility of immunosuppression in composite tissue allografts by systemic administration of CTLA4Ig
-
Iwasaki N, Gohda T, Yoshioka C et al. Feasibility of immunosuppression in composite tissue allografts by systemic administration of CTLA4Ig. Transplantation 73, 334-340 (2002).
-
(2002)
Transplantation
, vol.73
, pp. 334-340
-
-
Iwasaki, N.1
Gohda, T.2
Yoshioka, C.3
-
115
-
-
0029162499
-
Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig
-
Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J. Clin. Invest. 96, 987-993 (1995).
-
(1995)
J. Clin. Invest.
, vol.96
, pp. 987-993
-
-
Knoerzer, D.B.1
Karr, R.W.2
Schwartz, B.D.3
Mengle-Gaw, L.J.4
-
116
-
-
0028868424
-
CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system
-
Khoury SJ, Akalin E, Chandraker A et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155, 4521-4524 (1995).
-
(1995)
J. Immunol.
, vol.155
, pp. 4521-4524
-
-
Khoury, S.J.1
Akalin, E.2
Chandraker, A.3
-
117
-
-
0028900297
-
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the non-obese diabetic mouse
-
Lenschow DJ, Ho SC, Sattar H et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the non-obese diabetic mouse. J. Exp. Med. 181, 1145-1155 (1995).
-
(1995)
J. Exp. Med.
, vol.181
, pp. 1145-1155
-
-
Lenschow, D.J.1
Ho, S.C.2
Sattar, H.3
-
119
-
-
4644285392
-
E3 ubiquitin ligases as T-cell anergy factors
-
Mueller DL. E3 ubiquitin ligases as T-cell anergy factors. Nature Immunol. 5, 883-890 (2004).
-
(2004)
Nature Immunol.
, vol.5
, pp. 883-890
-
-
Mueller, D.L.1
-
120
-
-
1842607447
-
New immunosuppressive strategies in renal transplant recipients
-
Fischereder M, Kretzler M. New immunosuppressive strategies in renal transplant recipients. J. Nephrol. 17, 9-18 (2004).
-
(2004)
J. Nephrol.
, vol.17
, pp. 9-18
-
-
Fischereder, M.1
Kretzler, M.2
-
121
-
-
1642347770
-
FTY720 immunomodulation: Optimism for improved transplant regimens
-
Ferguson R. FTY720 immunomodulation: optimism for improved transplant regimens. Transpl. Proc. 36, S549-S553 (2004).
-
(2004)
Transpl. Proc.
, vol.36
-
-
Ferguson, R.1
-
122
-
-
3042743990
-
FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
-
Brinkmann V, Cyster JG, Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4, 1019-1025 (2004).
-
(2004)
Am. J. Transplant.
, vol.4
, pp. 1019-1025
-
-
Brinkmann, V.1
Cyster, J.G.2
Hla, T.3
-
123
-
-
0036285240
-
Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model
-
Konishi K, Inobe M, Yamada A et al. Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model. J. Heart Lung Transplant. 21, 692-700 (2002).
-
(2002)
J. Heart Lung Transplant.
, vol.21
, pp. 692-700
-
-
Konishi, K.1
Inobe, M.2
Yamada, A.3
-
124
-
-
0242332186
-
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
-
Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878 (2003).
-
(2003)
Science
, vol.302
, pp. 875-878
-
-
Changelian, P.S.1
Flanagan, M.E.2
Ball, D.J.3
-
125
-
-
3543141120
-
A new modality for immunosuppression: Targeting the JAK/STAT pathway
-
O'shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Naure. Rev. Drug Discovery 3, 555-564 (2004).
-
(2004)
Naure Rev. Drug Discovery
, vol.3
, pp. 555-564
-
-
O'shea, J.J.1
Pesu, M.2
Borie, D.C.3
Changelian, P.S.4
-
126
-
-
0038690324
-
Clinical trials of transplant tolerance: Slow but steady progress
-
Matthews JB, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: slow but steady progress. Am. J. Transplant. 3, 794-803 (2003).
-
(2003)
Am. J. Transplant.
, vol.3
, pp. 794-803
-
-
Matthews, J.B.1
Ramos, E.2
Bluestone, J.A.3
-
127
-
-
3042722261
-
Exploiting tolerance processes in transplantation
-
Waldmann H, Cobbold S. Exploiting tolerance processes in transplantation. Science 305, 209-212 (2004).
-
(2004)
Science
, vol.305
, pp. 209-212
-
-
Waldmann, H.1
Cobbold, S.2
-
128
-
-
3042819498
-
Surrogate markers for long-term renal allograft survival
-
Hariharan S, Kasiske B, Matas A et al. Surrogate markers for long-term renal allograft survival. Am. J. Transplant. 4, 1179-1183 (2004).
-
(2004)
Am. J. Transplant.
, vol.4
, pp. 1179-1183
-
-
Hariharan, S.1
Kasiske, B.2
Matas, A.3
-
129
-
-
2442647551
-
Dendritic cell immunotherapy: Mapping the way
-
Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nature Med. 10, 475-480 (2004).
-
(2004)
Nature Med.
, vol.10
, pp. 475-480
-
-
Figdor, C.G.1
De Vries, I.J.2
Lesterhuis, W.J.3
Melief, C.J.4
-
130
-
-
1642321113
-
Revival of the regulatory T-cell: New targets for drug development
-
Sutmuller RP, Offringa R, Melief CJ. Revival of the regulatory T-cell: new targets for drug development. Drug Discov. Today 9, 310-316 (2004).
-
(2004)
Drug Discov. Today
, vol.9
, pp. 310-316
-
-
Sutmuller, R.P.1
Offringa, R.2
Melief, C.J.3
-
131
-
-
2542476167
-
CD40/CD154 interactions at the interface of tolerance and immunity
-
Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Ann. Rev. Immunol. 22, 307-328 (2004).
-
(2004)
Ann. Rev. Immunol.
, vol.22
, pp. 307-328
-
-
Quezada, S.A.1
Jarvinen, L.Z.2
Lind, E.F.3
Noelle, R.J.4
-
132
-
-
12144288178
-
Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation
-
Schuler W, Bigaud M, Brinkmann V, et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 77, 717-726 (2004).
-
(2004)
Transplantation
, vol.77
, pp. 717-726
-
-
Schuler, W.1
Bigaud, M.2
Brinkmann, V.3
-
133
-
-
4344586455
-
CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates
-
Kawai T, Sogawa H, Boskovic S et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am. J. Transplant. 4, 1391-1398 (2004).
-
(2004)
Am. J. Transplant.
, vol.4
, pp. 1391-1398
-
-
Kawai, T.1
Sogawa, H.2
Boskovic, S.3
-
134
-
-
10744220010
-
Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates
-
Koyama I, Kawai T, Andrews D et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 77, 460-462 (2004).
-
(2004)
Transplantation
, vol.77
, pp. 460-462
-
-
Koyama, I.1
Kawai, T.2
Andrews, D.3
-
135
-
-
3342935958
-
Anti-CD3 antibodies: Towards clinical antigen-specific immunomodulation
-
Chatenoud L. Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. Curr. Opin. Pharmacol. 4, 403-437 (2004).
-
(2004)
Curr. Opin. Pharmacol.
, vol.4
, pp. 403-437
-
-
Chatenoud, L.1
-
136
-
-
3042847542
-
Immune therapy for autoimmune diseases
-
Steinman L. Immune therapy for autoimmune diseases. Science 305, 212-216 (2004).
-
(2004)
Science
, vol.305
, pp. 212-216
-
-
Steinman, L.1
-
138
-
-
0037413467
-
A controlled trial of natalizumab for relapsing multiple sclerosis
-
Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 15-23
-
-
Miller, D.H.1
Khan, O.A.2
Sheremata, W.A.3
|